T-PA suppresses the immune response and aggravates neurological deficit in a murine model of ischemic stroke

Frontiers in Immunology

Volumn 10, Issue MAR, 2019, Pages

  Draxler, Dominik F ^a   Lee, Felix ^a   Ho, Heidi ^a   Keragala, Charithani B ^a   Medcalf, Robert L ^a   Niego, Be'eri ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Immune system; Immunosuppression; MCAo; Plasminogen; Stroke; T PA

Indexed keywords

ALBUMIN; GAMMA INTERFERON; HUMAN RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR; INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CYTOKINE; PLASMIN; PLASMINOGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR ASSESSMENT; BLOOD CELL COUNT; BLOOD CLOT LYSIS; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; FLOW CYTOMETRY; HANGING WIRE TEST; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REPERFUSION; UPREGULATION; ANIMAL; BLOOD; C57BL MOUSE; CEREBROVASCULAR ACCIDENT; DISEASE MODEL; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE COUNT; MIDDLE CEREBRAL ARTERY; PATHOLOGY; PROCEDURES;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; FIBRINOLYSIN; IMMUNOMODULATION; LYMPHOCYTE COUNT; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE CEREBRAL ARTERY; PLASMINOGEN; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 85064722592     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2019.00591     Document Type: Article

References (33)

1. Thrift AG, Thayabaranathan T, Howard G, Howard VJ, Rothwell PM, Feigin VL, et al. Global stroke statistics. Int J Stroke. (2017) 12:13–32. doi: 10.1177/1747493016676285
2. Bhatia R, Hill MD, Shobha N, Menon B, Bal S, Kochar P, et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke. (2010) 41:2254–8. doi: 10.1161/STROKEAHA.110.592535
3. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. (2014) 384:1929–35. doi: 10.1016/S0140-6736(14)60584-5
4. Niego B, Medcalf RL. Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis? J Cereb Blood Flow Metab. (2014) 34:1283–96. doi: 10.1038/jcbfm.2014.99
5. Tsirka SE, Rogove AD, Bugge TH, Degen JL, Strickland S. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci. (1997) 17:543–52. doi: 10.1523/JNEUROSCI.17-02-00543.1997
6. Parcq J, Bertrand T, Montagne A, Baron AF, Macrez R, Billard JM, et al. Unveiling an exceptional zymogen: the single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity. Cell Death Differ. (2012) 19:1983–91. doi: 10.1038/cdd.2012.86
7. Vermeij JD, Westendorp WF, Roos YB, Brouwer MC, Van De Beek D, Nederkoorn PJ. Preventive ceftriaxone in patients with stroke treated with intravenous thrombolysis: post hoc analysis of the preventive antibiotics in stroke study. Cerebrovasc Dis. (2016) 42:361–9. doi: 10.1159/000446160
8. Draxler DF, Sashindranath M, Medcalf RL. Plasmin: a modulator of immune function. Semin Thromb Hemost. (2017) 43:143–53. doi: 10.1055/s-0036-1586227
9. Borg RJ, Samson AL, Au AE, Scholzen A, Fuchsberger M, Kong YY, et al. Dendritic cell-mediated phagocytosis but not immune activation is enhanced by plasmin. PLoS ONE. (2015) 10:e0131216. doi: 10.1371/journal.pone.0131216
10. Meisel C, Schwab JM, Prass K, Meisel A, Dirnagl U. Central nervous system injury-induced immune deficiency syndrome. Nat Rev Neurosci. (2005) 6:775–86. doi: 10.1038/nrn1765
11. Stanley D, Mason LJ, Mackin KE, Srikhanta YN, Lyras D, Prakash MD, et al. Translocation and dissemination of commensal bacteria in post-stroke infection. Nat Med. (2016) 22:1277–84. doi: 10.1038/nm.4194
12. Niego B, Broughton BRS, Ho H, Sobey CG, Medcalf RL. LDL receptor blockade reduces mortality in a mouse model of ischaemic stroke without improving tissue-type plasminogen activator-induced brain haemorrhage: towards pre-clinical simulation of symptomatic ICH. Fluids Barriers CNS. (2017) 14:33. doi: 10.1186/s12987-017-0081-2
13. Singh S, Houng AK, Wang D, Reed GL. Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis. J Thromb Haemost. (2016) 14:1822–32. doi: 10.1111/jth.13390
14. Lijnen HR, Van Hoef B, Beelen V, Collen D. Characterization of the murine plasma fibrinolytic system. Eur J Biochem. (1994) 224:863–71. doi: 10.1111/j.1432-1033.1994.00863.x
15. Petullo D, Masonic K, Lincoln C, Wibberley L, Teliska M, Yao DL. Model development and behavioral assessment of focal cerebral ischemia in rats. Life Sci. (1999) 64:1099–108. doi: 10.1016/S0024-3205(99)00038-7
16. Lijnen HR. Pathophysiology of the plasminogen/plasmin system. Int J Clin Lab Res. (1996) 26:1–6. doi: 10.1007/BF02644767
17. Moretti A, Ferrari F, Villa RF. Pharmacological therapy of acute ischaemic stroke: achievements and problems. Pharmacol Ther. (2015) 153:79–89. doi: 10.1016/j.pharmthera.2015.06.004
18. Draxler DF, Medcalf RL. The fibrinolytic system-more than fibrinolysis? Transfus Med Rev. (2015) 29:102–9. doi: 10.1016/j.tmrv.2014.09.006
19. Niego B, Freeman R, Puschmann TB, Turnley AM, Medcalf RL. t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes. Blood. (2012) 119:4752–61. doi: 10.1182/blood-2011-07-369512
20. Niego B, Lee N, Larsson P, De Silva TM, Au AE, Mccutcheon F, et al. Selective inhibition of brain endothelial Rho-kinase-2 provides optimal protection of an in vitro blood-brain barrier from tissue-type plasminogen activator and plasmin. PLoS ONE. (2017) 12:e0177332. doi: 10.1371/journal.pone.0177332
21. Wong CH, Jenne CN, Lee WY, Leger C, Kubes P. Functional innervation of hepatic iNKT cells is immunosuppressive following stroke. Science. (2011) 334:101–5. doi: 10.1126/science.1210301
22. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. (2015) 523:337–41. doi: 10.1038/nature14432
23. Miro-Mur F, Urra X, Gallizioli M, Chamorro A, Planas AM. Antigen presentation after stroke. Neurotherapeutics. (2016) 13:719–28. doi: 10.1007/s13311-016-0469-8
24. Lord JM, Midwinter MJ, Chen YF, Belli A, Brohi K, Kovacs EJ, et al. The systemic immune response to trauma: an overview of pathophysiology and treatment. Lancet. (2014) 384:1455–65. doi: 10.1016/S0140-6736(14)60687-5
25. Santos Samary C, Pelosi P, Leme Silva P, Rieken Macedo Rocco P. Immunomodulation after ischemic stroke: potential mechanisms and implications for therapy. Crit Care. (2016) 20:391. doi: 10.1186/s13054-016-1573-1
26. Shi K, Wood K, Shi FD, Wang X, Liu Q. Stroke-induced immunosuppression and poststroke infection. Stroke Vasc Neurol. (2018) 3:34–41. doi: 10.1136/svn-2017-000123
27. Ashour W, Al-Anwar AD, Kamel AE, Aidaros MA. Predictors of early infection in cerebral ischemic stroke. J Med Life. (2016) 9:163–9.
28. Siao CJ, Tsirka SE. Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. J Neurosci. (2002) 22:3352–8. doi: 10.1523/JNEUROSCI.22-09-03352.2002
29. Pineda D, Ampurdanes C, Medina MG, Serratosa J, Tusell JM, Saura J, et al. Tissue plasminogen activator induces microglial inflammation via a noncatalytic molecular mechanism involving activation of mitogen-activated protein kinases and Akt signaling pathways and AnnexinA2 and Galectin-1 receptors. Glia. (2012) 60:526–40. doi: 10.1002/glia.22284
30. Langhorne P, Stott DJ, Robertson L, Macdonald J, Jones L, Mcalpine C, et al. Medical complications after stroke: a multicenter study. Stroke. (2000) 31:1223–9. doi: 10.1161/01.STR.31.6.1223
31. Wartenberg KE, Stoll A, Funk A, Meyer A, Schmidt JM, Berrouschot J. Infection after acute ischemic stroke: risk factors, biomarkers, and outcome. Stroke Res Treat. (2011) 2011:830614. doi: 10.4061/2011/830614
32. Carmichael ST. Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx. (2005) 2:396–409. doi: 10.1602/neurorx.2.3.396
33. Campbell BC. Thrombolysis and thrombectomy for acute ischemic stroke: strengths and synergies. Semin Thromb Hemost. (2017) 43:185–90. doi: 10.1055/s-0036-1585078